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factors, OCT3/4, SOX2, cMYC, KLF4, using Sendai virus vector (SeVdp). The authenticity of established iPSC line,
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germ layers. LDS-iPSC8 may be a useful cell resource for the establishment of in vitro LDS modeling and the
study for vascular and lymph vessel development.
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Expanded T cells isolated from a patient with lymphedema-
distichiasis syndrome (LDS) were reprogrammed employing Sendai
virus vectors (SeVdp) expressing four reprogramming factors, OCT3/4,y, The Jikei University School of
8461, Japan.
. This is an open access article underSOX2, cMYC, KLF4. SeVdp is integration-free vector, and the absence of
reprogramming genes in established iPSC line, LDS-iPSC8, was con-
ﬁrmed by PCR analysis (Fig. 1A). The same pathogenic mutation in the
FOXC2 gene was also detected in genomic DNA isolated from LDS-
iPSC8 (Fig. 1B), proving the origin of cell source. The authenticity of
LDS-iPSC8 was conﬁrmed by the followings; (1) the expression of
stem cell markers by immunostaining (Fig. 1C) and RT-PCR (Fig. 1D),
(2) the differentiation capability into three germ layers using in vitro
differentiation through embryoid bodies (EBs) and teratoma formation
(Fig. 1E). In addition, LDS-iPSC8 maintains normal karyotype (46, XY)
(Fig. 1F), and bisulﬁte sequencing revealed that the NANOG promoter
region in LDS-iPSC8 was unmethylated (Fig. 1G).
2. Materials and methods
2.1. Patient information
The patient information can be referred in our previous case report
(Itoh and Nakagawa, 2013). Brieﬂy, the male patient had lower-limb
lymphedema appearing at the age of 18, and he was also diagnosed with
mild ventricular septal defect and blindness due to microphthalmia at
birth. Physical examination revealed distichiasis, i.e. multiple rows of eye-
lashes on the inferior and superior eyelids, and a saddle nose deformity.
The pathogenicmutationwas c.724_727delCGCAinsAG in the FOXC2 gene.
2.2. Cell culture
Monocytes were isolated from the patient's peripheral blood sample
using SepMate™-50 (STEMCELL technologies, Inc., Canada) and Ficoll-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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culture® kit (LYMPHOTEC, Inc., Japan) for 5–10 days at 37 °C at 5% CO2.
2.3. iPSC generation
Expanded T cells were transduced by SeVdp (multiplicity of infec-
tion = 2, at 37 °C for 2 h) expressing four reprogramming factors,
OCT3/4, SOX2, cMYC, KLF4 (Nishimura et al., 2011). The transduced
cells were seeded on X ray-irradiated mouse embryonic ﬁbroblast
(MEF) in human T cell medium (RPMI1640 with 10% fetal bovine
serum, 1% penicillin–streptomycin (Invitrogen) and Interleukin-2
(PeproTech)). After 2 days, the medium was changed to Primate ES
cell culture medium (ReproCELL Inc., Japan) supplemented with basic
ﬁbroblast growth factor (bFGF) (5 ng/mL, R&D Systems), and cultured
until colonies appeared. Colonies of iPSCs were mechanically picked
up and replaced on X ray-irradiated MEF for expansion and characteri-
zation. Established iPSCs were maintained in human iPS cell medium
(hiPSCM: DMEM/F12 (Sigma) supplemented with 20% knockout
serum replacement (Invitrogen), 1% nonessential amino acid
(Invitrogen), 0.1 mM 2-mercaptoethanol, 1% penicillin–streptomycin,
and 5 ng/mL bFGF). To completely remove SeVdp, siRNA mixture
(40 nM L527siRNA-1 and 2, 5 μL RNAiMAX (Invitrogen) in 500 μL
OptiMEM) was added several times into the medium. siRNAs are the
following; L527siRNA-1: 5′-GGUUCAGCAUCAAAUAUGAAG-3′, and
L527siRNA-2: 5′-UCAUAUUUGAUGCUGAACCAU-3′.
2.4. Sequencing
Sanger sequencing analysis of the mutation site in the FOXC2 gene
was performed in Applied Biosystems 3730xI DNA analyzer using the
ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit
ver. 3.1. (Applied Biosystems).
2.5. RT-PCR and PCR
RNAwas extracted using an RNeasy Mini Kit (Qiagen), and comple-
mentary DNAwas synthesized using 2 μg RNA by SuperScript III reverse
transcriptase and Oligo-dT primer (Invitrogen) according to the
manufacturer's instructions. PCR reactions were performed with Plati-
num PCR SuperMix (Invitrogen). All primer sequences are supplied in
Itoh et al. (2011). SeVdp: 5′-AGACCCTAAGAGGACGAAGA-3′, 5′-ACTC
CCATGGCGTAACTCCATAGTG-3′.
2.6. Immunostaining
iPSCs and EBs were ﬁxed with 4% paraformaldehyde(PFA)/PBS and
permeabilized with 0.1% Triton-X100/PBS. After blocking using 10%
goat sera/PBS, samples were incubated for 1 h at room temperature
(RT) or overnight at 4 °C with primary antibodies. After three rinses
with PBS, incubation with appropriate secondary antibodies was per-
formed for 1 h at RT. Nuclei stainingwas performedwith Hoechst33342
(1:1000, Fisher Scientiﬁc)/PBS. Conforcal microscopy (OLYMPUS FV-
300) was used to visualize and capture the immunostained cells with
good resolution. All antibodies are the follows; SSEA-4 (MerckMilliporeFig. 1. Characterization of LDS-iPSC8. (A) Conﬁrmation of the absent of SeVdp-related reprogr
(B) The same pathogenic mutation in the FOXC2 gene was detected from genomic DNA isola
immunostaining (C) and RT-PCR (D, red square) (E: embryonic stem cell cDNA, M: mono
capability into three germ layers, ectoderm (βIII-tubulin and neural epithelium), mesoderm (v
was normal (46, XY). (G) The NANOG promoter region in LDS-iPSC8 was almost completely u
data suggested the authenticity of LDS-iPSC8.MAB4304), TRA-1-60 (Merck Millipore MAB4360), TRA-1-81 (Merck
Millipore MAB4381), Alexa Fluor® 546 goat anti-mouse IgG (H + L)
(Thermo Fisher Scientiﬁc A11003), Alexa Fluor® 488 goat anti-mouse
IgM (μ-chain) (Thermo Fisher Scientiﬁc A21042).
2.7. Karyotyping analysis
Karyotyping analysis was offered to Nihon Gene Research Laborato-
ries, Inc., Japan.
2.8. Methylation assay
A total of 1 μg genomic DNA extracted from LDS-iPSC8 was treated
with EZ DNAMethylation-Gold Kit (ZYMO Research, Corp.) for bisulﬁte
reaction. The promoter region of theNANOG genewas ampliﬁed by PCR
using gene-speciﬁc primers (Itoh et al. 2011). PCR product was
subcloned into pCR2.1 vector (Invitrogen), and 5 clones were se-
quenced for deﬁningmethylation status of theNANOG promoter region.
2.9. In vitro differentiation
EBs were made in hiPSCM without bFGF as previously described in
Itoh et al. (2011). For enhancing spontaneous differentiation, EBs were
attached on gelatin-coated chamber slides and incubated in DMEM
with 10% FBS for 14 days before immunostaining.
2.10. Teratoma formation
Colonies of LDS-iPSC8 were collected by 1 mg/mL collagenase IV
(Invitrogen) treatment and subcutaneously injected into nude mice
(CLEA Japan, Inc.)withMatrigel (Corning, Inc.). Palpable tumors typical-
ly appeared 1–2 months after injection. Tumors were collected and
processed for H&E staining according to standard procedures to check
their differentiation capacity into all three germ layers in vivo.
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